WO2014186649A3 - Compositions and methods for treating hiv-1-associated chronic immune activation - Google Patents

Compositions and methods for treating hiv-1-associated chronic immune activation Download PDF

Info

Publication number
WO2014186649A3
WO2014186649A3 PCT/US2014/038310 US2014038310W WO2014186649A3 WO 2014186649 A3 WO2014186649 A3 WO 2014186649A3 US 2014038310 W US2014038310 W US 2014038310W WO 2014186649 A3 WO2014186649 A3 WO 2014186649A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
compositions
chronic immune
immune activation
methods
Prior art date
Application number
PCT/US2014/038310
Other languages
French (fr)
Other versions
WO2014186649A2 (en
Inventor
Mark A. BERNARD
Souvenir D. TACHADO
Original Assignee
Beth Israel Deaconess Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center, Inc. filed Critical Beth Israel Deaconess Medical Center, Inc.
Publication of WO2014186649A2 publication Critical patent/WO2014186649A2/en
Publication of WO2014186649A3 publication Critical patent/WO2014186649A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compositions and methods for treating HIV-associated chronic immune activation in HIV-positive patients, or for preventing the same in patients at risk of being infected by HIV. The compositions of the invention include antagomirs that antagonize the function of certain HIV-derived viral microRNA (vmiR), which vmiR may lead to chronic immune activation in HIV-positive patients by non-canonical activation of certain pro-inflammatory cytokine pathways.
PCT/US2014/038310 2013-05-17 2014-05-16 Compositions and methods for treating hiv-1-associated chronic immune activation WO2014186649A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361824764P 2013-05-17 2013-05-17
US61/824,764 2013-05-17
US201361876832P 2013-09-12 2013-09-12
US61/876,832 2013-09-12
US201461933393P 2014-01-30 2014-01-30
US61/933,393 2014-01-30

Publications (2)

Publication Number Publication Date
WO2014186649A2 WO2014186649A2 (en) 2014-11-20
WO2014186649A3 true WO2014186649A3 (en) 2015-01-22

Family

ID=51899013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/038310 WO2014186649A2 (en) 2013-05-17 2014-05-16 Compositions and methods for treating hiv-1-associated chronic immune activation

Country Status (1)

Country Link
WO (1) WO2014186649A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106177990B (en) * 2014-11-17 2020-08-28 江苏命码生物科技有限公司 New precursor miRNA and application thereof in tumor treatment
US10472408B2 (en) 2015-03-05 2019-11-12 Peter Und Traudl Engelhorn-Stiftung Zur Förderung Der Lebenswissenschaften Fusion proteins comprising partial tetraspanin sequences and a system thereof for presenting peptides on the cell surface
CN107151661A (en) * 2016-03-02 2017-09-12 上海润腾生物科技有限公司 A kind of people's excretion body protein, kit and its application
EP3758687A4 (en) * 2018-03-01 2022-03-30 Rhode Island Hospital Exosome targeting of cd4+ expressing cells
WO2019195179A1 (en) * 2018-04-02 2019-10-10 Capienda Biotech, Llc Compositions and methods for treating inflammatory diseases
WO2024073397A1 (en) * 2022-09-27 2024-04-04 The University Of North Carolina At Chapel Hill Synthetic tetraspanins and extracellular vesicles comprising the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080171716A1 (en) * 2006-08-16 2008-07-17 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
US20120225477A1 (en) * 2004-05-26 2012-09-06 Itzhak Bentwich Viral and viral associated mirnas and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225477A1 (en) * 2004-05-26 2012-09-06 Itzhak Bentwich Viral and viral associated mirnas and uses thereof
US20080171716A1 (en) * 2006-08-16 2008-07-17 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "microRNAs are ligands of Toll-like receptors.", RNA., vol. 19, no. 6, June 2013 (2013-06-01), pages 737 - 739 *
HAN ET AL.: "Epigenetic Regulation of Tumor Necrosis Factor alpha (TNFalpha) Release in Human Macrophages by HIV-1 Single-stranded RNA (ssRNA) Is Dependent on TLR8 Signaling.", J BIOL CHEM., vol. 287, no. 17, 20 April 2012 (2012-04-20), pages 13778 - 13786 *

Also Published As

Publication number Publication date
WO2014186649A2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
HK1251219A1 (en) Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
HUS2200053I1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP3332007A4 (en) Rnai therapy for hepatitis b virus infection
ZA201903906B (en) Phosphoramidates for the treatment of hepatitis b virus
HK1244281B (en) 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
EP3494123A4 (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3364983A4 (en) Respiratory virus vaccines
HK1223931A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EP3474863A4 (en) Phosphoramidates for the treatment of hepatitis b virus
EP3283472A4 (en) Hepatitis b viral assembly effectors
WO2014186649A3 (en) Compositions and methods for treating hiv-1-associated chronic immune activation
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3143144A4 (en) VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION
EP3103866A4 (en) Porcine pseudorabies virus attenuating method, viral strains attenuated thereby, vaccine composition and application thereof
EP3317290A4 (en) Compositions and methods for the treatment of viral infection
EP3400007A4 (en) Orthomyxo-like virus of tilapia
EP3137078A4 (en) Treatment of hepatitis delta virus infection
EP3370723A4 (en) Treatment of hepatitis delta virus infection
EP3057611A4 (en) Thermostable respiratory synctial virus (rsv) vaccine compositions
EP3226973A4 (en) Treatment of hepatitis delta virus infection
EP3091990A4 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
EP3565554A4 (en) Compounds, compositions, and methods for treating human immunodeficiency virus
EP3382012A4 (en) Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14797964

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14797964

Country of ref document: EP

Kind code of ref document: A2